Epothilone B enhances Class I HLA and HLA-A2 surface molecule expression in ovarian cancer cells (Q39534587)

12 September 2017

Epothilone B enhances Class I HLA and HLA-A2 surface molecule expression in ovarian cancer cells (English)

1 reference

12 September 2017

1 reference

Ilenia Pellicciotta

1

1 reference

12 September 2017

Chia-Ping Huang Yang

series ordinal

2

1 reference

12 September 2017

Gary L Goldberg

series ordinal

3

1 reference

12 September 2017

Shohreh Shahabi

series ordinal

4

1 reference

12 September 2017

language of work or name

English

0 references

publication date

28 May 2011

1 reference

12 September 2017

1 reference

12 September 2017

122

1 reference

12 September 2017

625-631

1 reference

12 September 2017

3

1 reference

Therapeutic effect against human xenograft tumors in nude mice by the third generation microtubule stabilizing epothilones

12 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Epothilones and new analogues of the microtubule modulators in taxane-resistant disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Epothilone B enhances surface EpCAM expression in ovarian cancer Hey cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Role of interferons and other cytokines in the regulation of the immune response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Negative signaling by anti-HLA class I antibodies is dependent upon two triggering events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

MHC class I antigens, immune surveillance, and tumor immune escape.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Cytokine induced modulation of MHC class I and class II molecules on human cervical epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

HLA class I antigen abnormalities and immune escape by malignant cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Chemotherapeutic agents targeting the tubulin cytoskeleton modify LPS-induced cytokine secretion by dendritic cells and increase antigen presentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Therapeutic cancer vaccines in combination with conventional therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Harnessing the immune response to treat cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Immunotherapy and chemotherapy--a practical partnership

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Combined chemoimmunotherapy of solid tumours: improving vaccines?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Correlation between HLA-A2 gene frequency, latitude, ovarian and prostate cancer mortality rates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Combination strategies for enhancing the efficacy of immunotherapy in cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Low-dose chemotherapeutic agents regulate small Rho GTPase activity in dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Expression of soluble interleukin-6 receptor in malignant ovarian tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Interleukin-6 and its receptor in cancer: implications for translational therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Interleukin-12: a proinflammatory cytokine with immunoregulatory functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

IFN-alpha in the generation of dendritic cells for cancer immunotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

APC activation by IFN-alpha decreases regulatory T cell and enhances Th cell functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

Type I interferons as vaccine adjuvants against infectious diseases and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

IL-1β-mediated signals preferentially drive conversion of regulatory T cells but not conventional T cells into IL-17-producing cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.007

10.1016/J.YGYNO.2011.05.007

7 January 2021

Identifiers

DOI

1 reference

12 September 2017

1 reference